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Keratinocyte-Specific Mesotrypsin Contributes to the
Desquamation Process via Kallikrein Activation and
LEKTI Degradation
Masashi Miyai1,3, Yuuko Matsumoto1,3, Haruyo Yamanishi1, Mami Yamamoto-Tanaka1,2, Ryoji Tsuboi2 and
Toshihiko Hibino1
Kallikrein-related peptidases (KLKs) have critical roles in corneocyte desquamation and are regulated by
lymphoepithelial Kazal-type inhibitor (LEKTI). However, it is unclear how these proteases are activated and
how activated KLKs are released from LEKTI in the upper cornified layer. Recently, we reported cloning of a PRSS3
gene product, keratinocyte-specific mesotrypsin, from a cDNA library. We hypothesized that mesotrypsin is
involved in the desquamation process, and the aim of the present study was to test this idea by examining the
effects of mesotrypsin on representative desquamation-related enzymes pro-KLK5 and pro-KLK7. Incubation of
mesotrypsin and these zymogens resulted in generation of the active forms. KLK activities were effectively
inhibited by recombinant LEKTI domains D2, D2–5, D2–6, D2–7, D5, D6, D6–9, D7, D7–9, and D10–15, whereas
mesotrypsin activity was not susceptible to these domains, and in fact degraded them. Immunoelectron
microscopy demonstrated that mesotrypsin was localized in the cytoplasm of granular cells and intercellular
spaces of the cornified layer. Proximity ligation assay showed close association between mesotrypsin and KLKs
in the granular to cornified layers. Age-dependency analysis revealed that mesotrypsin was markedly down-
regulated in corneocyte extract from donors in their sixties, compared with younger donors. Collectively, our
findings suggest that mesotrypsin contributes to the desquamation process by activating KLKs and degrading the
intrinsic KLKs’ inhibitor LEKTI.
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INTRODUCTION
Epidermal differentiation is precisely controlled, and the thick-
ness of the epidermis is maintained through constant shedding
of the outermost layers of corneocytes, a process known as
desquamation (Watt, 1989). Desquamation is accomplished by
the degradation of corneodesmosomes, which are involved in
corneocyte–corneocyte adherence (Caubet et al., 2004; Ishida-
Yamamoto and Kishibe, 2011). Corneodesmosomes are com-
posed of three major proteins: desmoglein 1, desmocollin, and
corneodesmosin. These proteins are proteolytically hydrolyzed
by a family of kallikrein-related peptidases (KLKs). Earlier
studies demonstrated that a trypsin-like enzyme (stratum
corneum tryptic enzyme) (Suzuki et al., 1993) and a
chymotrypsin-like enzyme (stratum corneum chymotryptic
enzyme) (Lundstrom and Egelrud, 1991) have roles in the
detachment of superficial corneocytes. Later, these proteases
were identified as KLK5 and KLK7, respectively (Caubet et al.,
2004). Recent investigations have suggested that other KLK–
related enzymes, including KLKs 6, 8, 10, 11, 13, and 14, are
also expressed in human epidermis, and it was suggested that
they may form a proteolytic cascade that results in desquama-
tion (Komatsu et al., 2007). All KLKs are synthesized as
proenzymes, and subsequently activated through mechanisms
that have not yet been established. KLK5 is thought to be the
initiator of this cascade, as it is capable of activating most of the
family members (Ishida-Yamamoto et al., 2011).
Desquamation is regulated not only by proteases involved
in the activation cascade but also by inhibitors such as
lymphoepithelial Kazal-type related inhibitor (LEKTI), a pro-
duct of the serine protease inhibitor Kazal-type 5 gene SPINK5
(Borgono et al., 2007; Roelandt et al., 2009). LEKTI consists of
15 serine protease-inhibitory domains and is believed to be
processed to single or multiple domains to facilitate specific
inhibition of particular proteases. Recently, LEKTI2 encoded
by SPINK9 was identified in the palmoplantar epidermis and
was found to show KLK5–specific inhibition (Brannstrom
et al., 2012). SPINK6 was isolated from human plantar
stratum corneum extracts as a selective inhibitor of KLK5, 7,
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and 14 (Meyer-Hoffert et al., 2010). Thus, KLK activities seem
to be strongly suppressed under physiological conditions.
It is suggested that active KLKs are dissociated from various
SPINK gene products under acidic conditions at the skin
surface (Pampalakis and Sotiropoulou, 2007). However,
Ishida-Yamamoto et al. (2012) clearly demonstrated that
degradation of corneodesmosomes starts deeper in the corni-
fied layers. Thus, it is plausible that dissociation of active KLKs
from their inhibitors is not a cell-surface event, but is
controlled at least in part by mechanisms other than pH.
On the other hand, we have cloned an epidermis-specific
splicing variant of PRSS3 gene, trypsinogen 5, from a kerati-
nocyte cDNA library (Nakanishi et al., 2010). Trypsinogen 5
possesses a very short N-terminal propeptide followed by the
enterokinase recognition sequence DDDDK-I. After cleavage
by enterokinase, the same mesotrypsin would be produced as
from pancreatic trypsinogen 3 and brain-type trypsinogen 4.
We confirmed that epidermal mesotrypsin is expressed in the
upper epidermis, whereas its activating enzyme, enterokinase,
shows a more confined localization in the boundary area
between the granular layer and cornified layer. Characteristic
features of mesotrypsin are as follows: (1) it cannot digest high-
molecular-weight proteins, in contrast to anionic trypsin and
cationic trypsin, the PRSS1 and PRSS2 gene products,
respectively, and (2) it is not susceptible to naturally
occurring trypsin inhibitors (Nyaruhucha et al., 1997). Thus,
the physiological role of mesotrypsin is likely to be completely
different from those of trypsins. Instead, it seems likely to be
involved in limited proteolysis, such as zymogen activation.
Furthermore, it is capable of inactivating naturally occurring
trypsin inhibitors by proteolytic cleavage. These unique pro-
perties of mesotrypsin led us to hypothesize that epidermal
mesotrypsin is involved in the desquamation process. To test
this idea, we focused on two critical processes. One is the
activation of pro-KLK5 and the other is dissociation of active
KLKs from LEKTI proteins. Furthermore, we examined the
localization of mesotrypsin in human epidermis using
immunoelectronmicroscopy. Further, in situ proximity ligation
assay (PLA) was used to assess the interaction of mesotrypsin
with KLKs or LEKTI proteins in human epidermis.
RESULTS
Mesotrypsin activates epidermal prokallikreins
Epidermal kallikreins are all synthesized as inactive proen-
zymes that require proteolytic activation by cleavage. Meso-
trypsin is expressed in the upper granular and transitional cell
layers, where KLKs are also synthesized and secreted during
terminal differentiation. Therefore, mesotrypsin and pro-KLKs
may interact in this region. We focused on KLK5 and KLK7 as
representative desquamation-related proteases, as KLK5 acti-
vates all other pro-KLKs so far tested (Bratts and et al., 2005)
and KLK7 is one of the most abundant proteases expressed in
the epidermis (Ovaere et al., 2009). In the presence of
mesotrypsin, a 26-kDa band corresponding to active KLK5
was generated from pro-KLK5 in a dose-dependent manner
(Figure 1a). In contrast, the incubation of pro-KLK5 alone
resulted in no change. Time-course analysis confirmed con-
version of pro-KLK5 to its active form by treatment with
mesotrypsin (Figure 1b). In addition, incubation of pro-KLK5
with mesotrypsin resulted in a time-dependent linear increase
of KLK5 activity (Figure 1c). Similar results were obtained for
pro-KLK7 (Figure 1d–f). These results clearly indicate that
mesotrypsin generates active KLKs through limited proteolysis
of pro-KLKs.
Inhibition of KLK5 by LEKTI domains and the effect of pH on the
interaction
Next, we generated various fragments of LEKTI (D2, D2–5,
D2–6, D2–7, D5, D6, D7, D7–9, D8–9, and D10–15),
covering the whole length of the LEKTI protein (Figure 2a).
All of these LEKTI fragments were able to inhibit KLK5 activity
(Figure 2b). The inhibitory concentration 50 (IC50) values are
shown in Figure 2c. D2 showed a high IC50 value for KLK5
compared with other domains, indicating that D2 may not be
an effective inhibitor of KLK5. Similarly, all LEKTI fragments
were able to inhibit KLK7 activity (Supplementary Figure S1
online). Each domain construct showed somewhat weaker
inhibition of KLK7, compared with KLK5, and none of these
LEKTI domains showed a clear preference for KLK7 inhibition.
Next, we tested whether inhibition of KLK5 by LEKTI domains
was abrogated under acidic conditions (Figure 2d). KLK5 was
incubated with D5 or D6 in buffers of different pH values.
KLK5 was active between pH 5.5 and pH 9, and D5 and D6
completely suppressed KLK5 activity in this pH range. These
results indicate that loss of LEKTI inhibition of KLKs may not
occur simply as a result of the acidic pH typically observed at
the skin surface.
Mesotrypsin degrades various LEKTI domains
Next, we tested the effect of these LEKTI constructs on the
activity of mesotrypsin (Figure 3a). None of these LEKTI
constructs inhibited mesotrypsin activity even in the presence
of 1,000-fold excess of recombinant LEKTIs. These results
indicate that mesotrypsin is resistant to intrinsic serine pro-
tease inhibitors, including LEKTI. We then examined whether
the LEKTI constructs were degraded by mesotrypsin, using
newly prepared antibodies against D2 and D12, and commer-
cially available anti-D4–8 antibody (F2). The N-terminal
domains of LEKTI (D2 and D2–7), the inner domains (D5,
D6, D7, and D8–9), and the C-terminal domains (D10–15) all
disappeared after incubation with mesotrypsin (Figure 3b).
Next, we investigated the effect of mesotrypsin on the
recovery of KLK activities from the LEKTI-inhibited condition
(Figure 3c). As shown in the Supplementary Information
online and Supplementary Figure S2a online, enzyme activ-
ities of KLK5 and KLK7 were almost completely suppressed by
each of the LEKTI domains D2–7, D7–D9, and D10–15. We
selected these three recombinant proteins to cover the whole
of the LEKTI inhibitory domains. Addition of active mesotryp-
sin to the KLK5–LEKTI mixtures resulted in gradual recovery of
KLK5 activity. Recovery of KLK activities was evident for each
of the LEKTI domains, although the rate varied depending on
the particular inhibitory domain. Similar results were obtained
for KLK7. Thus, not only is mesotrypsin not susceptible to
LEKTI but also it has the ability to destroy LEKTI domains even
in the enzyme–inhibitor complex.
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We also tested the presence of LEKTI fragments in human
cornified cell extracts. Western blot analysis demonstrated
three major bands of 65, 27, and 65 kDa that were visualized
with anti-D2, anti-D4–8, and anti-D12 antibodies, respec-
tively (Supplementary Figure S2b online). Considering their
molecular weights and reactivity to antibodies, these bands
may correspond to D2–7, D7–9, and D10–15 fragments.
There were also several additional bands that were detected
with each antibody, although they seemed less abundant.
Spatiotemporal localization of mesotrypsin enables interaction
with target molecules in the human epidermis
To find out whether mesotrypsin can participate in the
desquamation process in vivo, we carried out immunoelectron
microscopy to examine its localization. Strong immunoreac-
tivity of mesotrypsin was associated with filamentous struc-
tures in the cytoplasm of granular cells, although not forming
particular patterns, whereas immunoreactivity was sparsely
distributed on spinous cells (Figure 4a). In addition, immunor-
eactivity was found broadly in interstitial spaces of cornified
layers, with some dense aggregates. We further examined
whether mesotrypsin and KLKs are associated with each other
in the human epidermis, using the in situ PLA method to
visualize protein–protein interactions on tissue sections. PLA
indicated that mesotrypsin interacts with KLK5 and KLK7
(Figure 4b). Strong signals were detected at the boundary area
between the granular and cornified layers, and some dotted
patterns were observed in the cornified layer. Interaction of
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Figure 1. Activation of prokallikrein-related peptidase 5 (pro-KLK5) and pro-KLK7 by mesotrypsin. (a) Western blot analysis of conversion of pro-KLK5
to its active form. Pro-KLK5 (arrowhead) was incubated with different concentrations of mesotrypsin as indicated in the figures for 60 minutes. Pro-KLK5 was
converted to the active form (arrow) by mesotrypsin in a dose-dependent manner (star indicates a nonspecific band). (b) Time-course analysis of pro-KLK5
conversion. Pro-KLK5 (arrowhead) was incubated with or without mesotrypsin for up to 60 minutes, and cleavage products were analyzed by western blot
analysis. The active form of KLK5 (arrow) was detected after treatment with mesotrypsin in a time-dependent manner, whereas no active form was detected in the
absence of mesotrypsin (star indicates a nonspecific band). (c) Measurement of enzymatic activity after the pro-KLK5 conversion. Pro-KLK5 was incubated with or
without mesotrypsin for 30 minutes. Fluorescence emission was recorded after the addition of the fluorogenic substrate. Assay mixtures containing pro-KLK5
and mesotrypsin showed a marked increase of hydrolytic activity (closed circles), compared with pro-KLK5 alone (open diamonds). Experiments were performed in
triplicate. Data are shown as mean fluorescence±SD. (d) Prepro-KLK7 (open arrowhead) decreased with time, and pro-KLK7 (filled arrowhead) was generated,
being finally converted to the active form (arrow). (e) Time-course analysis of pro-KLK7 conversion. The incubation of prepro-KLK7 (open arrowhead) with
mesotrypsin generated pro-KLK7 (filled arrowhead), which was converted to active KLK7 (arrow) in a time-dependent manner. (f) Measurement of enzymatic
activity after pro-KLK7 conversion. Assay mixtures containing pro-KLK7 and mesotrypsin showed a linear increase of hydrolytic activity (closed circles),
whereas pro-KLK7 alone showed no detectable activity during the 120-minute incubation time (open circles). Stability of mesotrypsin in the mixture was also
confirmed by immunoblotting using the same samples, as shown in the lower panels of a, b, d, and e.
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Figure 2. Effect of recombinant lymphoepithelial Kazal-type inhibitor (LEKTI) domains on kallikrein-related peptidase 5 (KLK5). (a) Schematic illustration of
recombinant LEKTI fragments. His-tag recombinants were expressed in Escherichia coli and were purified with Ni-Agarose, followed by anion-exchange Mono Q
chromatography (GE Healthcare, Wauwatosa, WI). (b) Effect of recombinant LEKTI domains on KLK5. Inhibitor activity on KLK5 was tested for each LEKTI
fragment. (c) Summary of inhibitory concentration 50 (IC50) values. Calculated IC50 values of recombinant LKETI fragments are listed. (d) Effect of pH on KLK5–
LEKTI relationship. KLK5 was incubated with each LEKTI fragment in buffers of various pH values ranging from 4 to 9, and inhibitory activity was measured. Closed
circles indicate KLK5 activities in various pH buffers. Open triangles and diamonds show inhibition on KLK5 in the presence of D5 (left) or D6 (right), respectively.
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mesotrypsin with KLK5 seems to start in upper spinous cells,
whereas that with KLK7 is more confined to granular cells.
Age dependence of mesotrypsin expression
It is suggested that desquamation ability decreases with
advanced age. Therefore, we examined age-related changes
of mesotrypsin expression in extracts obtained from tape-
stripped samples of forearm skin (Figure 5). Amounts of
mesotrypsin were measured in each 10-year age group from
20 to 69 years. Younger age groups showed relatively high
mesotrypsin expression (about 0.4 ng ml), and this level was
maintained up to the age group of 50–59 years. However,
tissue samples from the oldest age group (60–69 years)
showed a markedly lower concentration of mesotrypsin.
DISCUSSION
In the present study, we focused on the physiological role of
mesotrypsin in the human epidermis. Intense staining of
mesotrypsin in the upper epidermis, especially in the granular
layer, and confined localization of its activator enzyme,
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Figure 3. Degradation of lymphoepithelial Kazal-type inhibitor (LEKTI) domains by mesotrypsin. (a) The same recombinant proteins were tested for
inhibitory activities on mesotrypsin. None of these proteins showed any inhibitory effect on mesotrypsin. (b) Western blot analysis of mesotrypsin–LEKTI
interaction. After incubation of the assay mixture for up to 60 minutes, LEKTI domains were analyzed by western blot analysis with anti-D2, anti-D4–8, and
anti-D12 antibodies. (c) Recovery of kallikrein-related peptidase 5 (KLK5) (upper panel) and KLK7 activities (lower panel) from the LEKTI-inhibited state.
The effect of mesotrypsin on KLK–LEKTI complexes was investigated under the condition of 100% KLK inhibition by LEKTI domains D2–7, D7–9, and D10–15.
After enzyme–inhibitor (E–I) complex formation, mesotrypsin was added and recovery of KLK activities was measured at 15, 30, 45, and 60 minutes
(closed circles). In separate experiments, KLK activities were monitored in the absence of mesotrypsin (open circles).
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enterokinase, in granular cells strongly suggests that meso-
trypsin has a role in keratinocyte terminal differentiation
(Nakanishi et al., 2010). The present study is, to our know-
ledge previously unreported, to evaluate the possible role of
mesotrypsin in the desquamation process. Our results indicate
that mesotrypsin contributes to desquamation through
activation of at least two key zymogens, pro-KLK5 and
pro-KLK7, and also through degradation of intrinsic
multidomain KLK inhibitors, LEKTIs.
Mesotrypsin is different from other trypsins or trypsin-like
enzymes, including KLKs, in having a unique amino-acid
substitution in the reaction pocket (Szepessy and Sahin-Toth,
2006). It possesses the bulky amino-acid Arg instead of the
small amino-acid Gly, resulting in limited ability to hydrolyze
Granular cell Cornified layer
500 nm
200 nm200 µm
Mesotrypsin and normal IgG Mesotrypsin and KLK5 Mesotrpsin and KLK7
100 µm
Figure 4. Ultrastructural localization of mesotrypsin and its interaction with kallikrein-related peptidases (KLKs). (a) Imunoelectronmicroscopy of mesotrypsin.
(A) Upper epidermis, especially granular cells (indicated with dotted line), shows strong immunoreactivity for mesotrypsin. Bar¼ 500 nm. (B) Immunoreactivity in
the intercellular spaces of the cornified layer. Arrowheads indicate immunoreactivity for mesotrypsin in the cornified layer. Note the localization between
detached corneocytes. Bar¼ 100mm. (C) Another field showing localization of mesotrypsin in the cornified layer. Bar¼200mm. (D) A higher-magnification view
of the rectangular area marked in B. Dense aggregates of mesotrypsin immunoreactivity were frequently found in the intercellular spaces of the cornified layer.
Bar¼200 nm. (b) Interaction of mesotrypsin and KLKs evaluated with the PLA method. Close association between mesotrypsin and KLK5 is shown in the middle
panel. Strong positive signals were detected at the granular layer. Less marked but still clear signals were found in the cornified layer (bottom). Similarly,
mesotrypsin and KLK7 were closely associated in the granular layer and also to some degree in the cornified layer (right panel). Isotypic normal IgG did not show
any positive reaction (left panel). An enlarged figure is shown at the bottom. Dotted line indicates the boundary of the skin surface. Broken line shows the
epidermal–dermal junction. Bars¼10mm.
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high-molecular-weight proteins because of steric hindrance.
Substitution of Arg for Gly also makes mesotrypsin insuscep-
tible to intrinsic serine protease inhibitors. These characteristic
features of mesotrypsin distinguish it from other epidermal
proteases that are tightly regulated by various inhibitors, and
suggest that its role is to modulate physiological reactions by
limited proteolysis of key protein(s).
Increasing evidence supports a leading role of epidermal
KLKs in desquamation, specifically in the degradation of
extracellular corneodesmosomal proteins. Interestingly, KLK5
is able to activate most, if not all, other KLK family members
(Ishida-Yamamoto and Kishibe, 2011). Furthermore, KLK5
degrades the three major corneodesmosomal proteins corneo-
desmosin, desmoglein 1, and desmocollin 1 (Caubet et al.,
2004). Similar to KLK5, KLK7 also has strong proteolytic
activity toward corneodesmosin and desmocollin 1 (Caubet
et al., 2004). KLK 6, 8, 10, 11, 13, and 14 protein levels in the
stratum corneum have been quantified, and these molecules
were shown to degrade desmoglein 1 (Brattsand et al., 2005).
KLK14, which is highly expressed in plantar epidermis, could
activate pro-KLK5, but not pro-KLK7 or itself (Stefansson et al.,
2006).
On the basis of these findings, KLK5 appears to be a key
enzyme in the desquamation protease cascade. Nevertheless,
the activation mechanism of pro-KLK5 is still obscure. Although
pro-KLK5 can autoactivate under certain circumstances, this is
a very slow process (Pampalakis and Sotiropoulou, 2007).
It was recently suggested that KLK5 is activated by matriptase,
a type II membrane protease (Sales et al., 2010). Matriptase-
deficient mice showed a severe barrier defect, in addition
to a defect of profilaggrin processing (List et al., 2003;
Scharschmidt et al., 2009). In humans, loss-of-function
mutation of matriptase causes autosomal recessive ichthyosis
with hypotrichosis, which is characterized by hyperkeratosis,
defective corneocyte maturation, and interlamellar lipid
extrusion (Basel-Vanagaite et al., 2007; List et al., 2007).
Matriptase is a trypsin-like serine protease and is able to
activate pro-KLK5 in vitro (Netzel-Arnett et al., 2006). It may
also be involved in desquamation.
As far as inhibitors are concerned, LEKTI, a SPINK5 gene
product, is implicated in regulation of the desquamation
protease cascade (Schechter et al., 2005; Borgono et al.,
2007). This is supported by the fact that SPINK5 deficiency
causes Netherton syndrome, an autosomal recessive ichthyosis-
form disease characterized by dry skin, overdesquamation,
hair abnormality, and atopy (Ishida-Yamamoto et al., 2005;
Sun and Linden, 2006; Fortugno et al., 2011). LEKTI consists
of 15 Kazal-type serine protease domains and is processed
to a series of single- or multidomain inhibitors. We prepared
recombinant LEKTI domains of various sizes, covering the
whole length of LEKTI, and examined their inhibitory activities
toward KLK5, KLK7, and mesotrypsin. KLK5 was strongly
inhibited by all the recombinant LEKTI domains except D2.
The Kazal consensus sequence was best conserved in D2 and
D15, and constructs containing these domains showed rather
weak inhibition of KLK5. The strongest inhibition of KLK5 was
observed with D5 and D6, and fragments containing them
were detected in corneocyte extracts in our study. Furthermore,
we confirmed that at least D5, as well as D6, completely
suppressed KLK5 and KLK7 activities in the pH range of 5.5–9,
where KLKs are enzymatically active. Although it has been
proposed that KLKs are dissociated under acidic conditions
(around pH 5) at the skin surface (Deraison et al., 2007), it
would be difficult to generate active KLKs at this relatively
weak acidic pH, because (1) at pH 5.5 KLK activities were
completely suppressed by LEKTI domains, and (2) at pH 5.0
KLKs were inactivated. On the other hand, mesotrypsin was
completely resistant to all of these recombinant LEKTI
domains; in fact, it degraded these inhibitor proteins. This is
in accordance with previous findings that human mesotrypsin
cleaves the reactive-site peptide bond of Kunitz-type soybean
trypsin inhibitor and degrades Kazal-type pancreatic secretory
trypsin inhibitor (Szmola et al., 2003; Sahin-Toth, 2005).
Furthermore, we demonstrated that mesotrypsin is able to
degrade multiple LEKTI domains not only in the free state but
also in the enzyme–inhibitor complex. These lines of evidence
suggest that mesotrypsin is likely to be an initiator of
desquamation.
The localization of mesotrypsin indicated that it would be
involved in physiological reactions in the cytoplasm of
granular cells and intercellular spaces of the cornified layer.
KLKs are incorporated into lamellar bodies and secreted from
the apical surface of granular cells (Ishida-Yamamoto et al.,
2004). Although it has been believed that KLKs are released
from inhibitors and degrade corneodesmosomes in the stratum
corneum, our recent study suggested that KLK5 is also present
in the cytoplasm of granular cells and may participate in the
processing of profilaggrin (Sakabe et al., 2013). This in turn
may suggest that activation of KLKs occurs before secretion.
Indeed, the results of PLA analysis indicated that KLK5 is
associated with mesotrypsin below the granular layer.
The physiological roles of KLKs may not be limited to
desquamation. KLKs are expressed in many tissues, including
cancer cells, and aberrant expression of KLKs is often seen in
human malignancies. KLK3 or prostate-specific antigen is the
most widely known KLK owing to its application in diagnosis
and monitoring of prostate cancer (LeBeau et al., 2010).
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Figure 5. Age-dependent change of mesotrypsin. Amounts of mesotrypsin
in extracts from tape-stripped corneocytes were measured using the
mesotrypsin ELISA assay. Age groups of corneocyte donors covered each
decade from the twenties to the sixties.
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Emerging evidence suggests a number of critical functional
roles for KLKs in the pathogenesis of cancer, and they are
considered to be potential therapeutic targets (Andrade et al.,
2010). It would be interesting to know whether mesotrypsin is
expressed in cancer cells.
Epidermal mesotrypsin showed a marked decrease in tissue
from subjects in the 60 to 69 age group. It is well known
that with advancing age the skin shows reduced epidermal
proliferation associated with slower desquamation of the
stratum corneum (Tagami, 2008). Although intercellular lipid
production is also reduced in aged epidermis, the effect of this
is compensated by a thicker SC due to retardation of the
desquamation process. These changes may be related to the
downregulation of mesotrypsin in aged skin.
On the basis of our findings, we propose the mechanism of
desquamation shown in Figure 6. Epidermal mesotrypsin is
activated by enteropeptidase in the granular layer and then
processes pro-KLK5 and pro-KLK7 to their active forms. It also
degrades various forms of KLK-inhibitory LEKTI, allowing
KLKs to initiate degradation of corneodesmosomes. Thus,
epidermis-specific mesotrypsin contributes to the des-
quamation process in two ways: via activation of pro-KLKs
and via degradation of the intrinsic KLK inhibitor LEKTI.
Dysfunction of mesotrypsin regulation might therefore easily
affect terminal differentiation, resulting in various physiologi-
cal disorders. Thus, the present findings throw light on
keratinocyte biology, especially in relation to diseases asso-
ciated with aberrant keratinization, including deregulated
desquamation.
MATERIALS AND METHODS
Antibodies and proteins
Monoclonal anti-KLK5 antibody, recombinant active human
kallikrein 5, and recombinant active human trypsin 3/PRSS3
(mesotrypsin) were purchased from R&D Systems (Minneapolis,
MN). Monoclonal anti-KLK7 antibody and monoclonal anti-LEKTI
(F-2) antibody were purchased from Santa Cruz Biotechnology (Santa
Cruz, CA).
Preparation of anti-LEKTI-D2 and anti-LEKTI-D12 antibodies
Antibodies against human LEKTI D2 sequence (DDFKKGERDGDFIC)
and against human LEKTI D12 sequence (CTRESDPVRGPDGKTHGNK)
were raised in rabbits (Supplementary Table S1 online). Monospecific
anti-LEKTI D2 antibody and anti-LEKTI D12 antibody were purified
from the respective sera using NHS-activated Sepharose 4B Fast Flow
(GE Healthcare) conjugated with the antigen peptide.
Preparation of pro-KLK5
Pro-KLK5 PCR products were generated in wheat germ lysate to
achieve efficient translation. The first PCR was performed using the
adapter primers, a forward primer 50-CTTTAAGAAGGAGATATCA-
TATGAACAACGACGTGAGCTGTG-30 and a reverse primer 50-TGA
TGATGAGAACCCCCCCCTTAATGGTGGTGATGGTGGTGC-30, and
the second amplification step was carried out by the RTS Wheat
Germ Linear Template Generation Set, His-tag (Roche Diagnostics,
Indianapolis, IN) according to the manufacturer’s instructions. The
PCR product was inserted into the pIVEX1.3WG vector. Recombinant
pro-KLK5 was expressed at 24 1C, 900 r.p.m. for 24 hours using the
RTS 500 Wheat- Germ CECF Kit (Roche Diagnostics).
Preparation of various LEKTI constructs
Constructs for LEKTI domains were generated by PCR amplification of
cDNA from a skin extract, using various primers (Supplementary
Table S2 online). LEKTI fragments were cloned into pQE30, pQE100
(Qiagen, Valencia, CA), or pET30a (Novagen, Madison, WI).
Enzyme assays
Recombinant pro-KLK5 or pro-KLK7 was incubated alone or with
mesotrypsin in the assay buffer (100 mM Tris-HCl, pH 8.0, 0.1%
Tween-20, 1 mM CaCl2) at 37 1C for 30 minutes. The fluorogenic
substrate Boc-Gln-Ala-Arg-AMC for KLK5 or Boc-Val-Pro-Arg-AMC
(Peptide Institute, Osaka, Japan) for KLK7 was then added to a
0.01 mM final concentration, and fluorescence was measured using a
2030 Multilabel Reader ARVO X3 (Perkin-Elmer, Waltham, MA) with
excitation at 355 nm and emission at 460 nm. All experiments were
performed in triplicate and repeated at least two times. For inhibitor
assays, recombinant mature KLK5, KLK7, or active mesotrypsin was
incubated with various LEKTI fragments at 37 1C for 30 minutes. The
fluorogenic substrate was then added to the assay mixture (0.01 mM
final concentration), and fluorescence was measured as described
above.
Recovery of KLK activities from LEKTI-inhibited condition
Recombinant pro-KLK5 (10ml, 5 ng ml 1) or pro-KLK7 (10ml,
5 ng ml 1) was mixed with LEKTI domains (D2–7, D7–9, or D10–
15) in the assay buffer and kept at room temperature for 10 minutes.
Amounts of recombinant LEKTI domains were determined from the
inhibition curve, based on the calculated value of 100% inhibition for
each recombinant. Then, 10ml of active mesotrypsin (10 ng ml 1)
and Boc-Gln-Ala-Arg-AMC (0.01 mM final concentration) were added
to the mixture, and recovery of KLK activities was monitored at 15,
30, 45, and 60 minutes.
Western blot analysis
After electrophoresis, proteins were transferred from polyacrylamide
gel onto polyvinylidene difluoride membranes using the iBlot Dry
Blotting System (Invitrogen, Carlsbad, CA). ImmunoBlock (DS Pharma
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Figure 6. Proposed mechanism of desquamation. Epidermal mesotrypsin is
activated by enteropeptidase at the granular layer, and processes prokallikrein-
related peptidase 5 (Pro-KLK5) and pro-KLK7 to their active forms.
Furthermore, mesotrypsin degrades various forms of the KLK inhibitor LEKTI
(lymphoepithelial Kazal-type inhibitor), resulting in the appearance of KLK
activities. This initiates degradation of corneodesmosomes.
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Biomedical, Osaka, Japan) was used for blocking nonspecific reac-
tion. Membranes were subsequently incubated with anti-LEKTI D2
antibody, anti-LEKTI antibody (F-2), or anti-LEKTI D12 antibody for
1 hour at room temperature, followed by horseradish peroxidase–
conjugated anti-mouse IgG or horseradish peroxidase–conjugated
anti-rabbit IgG (GE Healthcare). Immunoreactive proteins were
visualized using ECL Plus (GE Healthcare).
Tissue specimens
This study was approved by the Ethical Committee of Tokyo Medical
University and the Shiseido Committee on Human Ethics. Human
skin tissues were obtained at plastic surgery, in accordance with the
Declaration of Helsinki Principles.
Immunoelectron microscopy
Parts of the specimens were immediately cut into small blocks and
fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS),
embedded in OTC compound (Sakura Finetek, Tokyo, Japan).
Cryosections were immunostained with rabbit anti-trypsin antibody
(Athens Research & Technology, Athens, GA). After incubation with
biotinylated anti-rabbit IgG antibody (Jackson ImmunoResearch
Laboratories, West Grove, PA), sections were reacted with AlexaFluor
488-FluoroNanogold-Streptavidin (Nanoprobes, Yaphank, NY), Vec-
tastain ABC Kit (Vector Laboratories, Burlingame, CA), and 3,30-
diaminobenzidine, according to the manufacturer’s instructions.
Following the silver enhancement step, specimens were postfixed
with 3% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4), followed
by 1% osmium tetroxide, dehydrated in a graded series of alcohol,
infiltrated with propylene oxide, and embedded in Epon–Araldite.
Sections were cut at 80 nm and examined with a transmission
electron microscope H-7100 (Hitachi High-Tech, Tokyo, Japan).
Proximity ligation assay
PLA reaction was performed using combinations of monoclonal
antitrypsin antibody and anti-KLK5 antibody, and rabbit antitrypsin
antibody and monoclonal anti-KLK7 antibody, respectively, accord-
ing to the manufacturer’s instructions. Antibody dilution used was
0.5mg ml 1 for each antibody.
Mesotrypsin ELISA assay
Briefly, 4mg ml 1 of antitrypsin antibody in PBS was immobilized by
overnight incubation on a 96-well plate. The plate was washed with
PBS containing 0.1% Tween-20 (PBS-T), nonspecific binding was
blocked with ImmunoBlock (Dainippon Sumitomo Pharma, Osaka,
Japan), and samples were incubated for 2 hours at 37 1C. The plate
was washed with PBS-T, and then 0.9mg ml 1 of anti-mesotrypsin
antibody (Lifespan Bioscience, Seattle, WA) was applied and the plate
was incubated for 1 hour at 37 1C. After incubation with horseradish
peroxidase–conjugated anti-mouse Fab (Sigma, St Louis, MO), color
was developed using the TMB Peroxidase EIA Substrate Kit (Bio-Rad
Laboratories, Hercules, CA). Absorbance was read at 450 nm after
stopping the reaction with 1 M sulfuric acid. Trypsin (Sigma) was used
as a standard to quantify mesotrypsin.
Statistical analysis
Data are expressed as the mean±SE. We used simple pairwise
comparison with Student’s t-test (two-tailed distribution with two-
sample equal variance). Po0.05 was considered significant.
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